New trial
Phase II venetoclax (BCL2 inhibitor) plus acalabrutinib in first-line CLL/SLL
- Trial ID
- NCT07014917 on ClinicalTrials.gov
- Cancer type
- CLL / SLL
- Stage of research
- Exploratory
- Published in
- New in Oncology - June 27, 2025
This randomized Phase II study compares intermittent (7-day) versus continuous (28-day) venetoclax dosing with acalabrutinib in previously untreated CLL/SLL patients. Conducted in Cincinnati, the trial aims to determine the optimal dosing schedule for efficacy and safety.
More in chronic lymphocytic leukemia
-
New trial · Oct 22, 2026 · NCT07847957
Phase 1b/2 roginolisib PI3K-delta inhibitor with sequential obinutuzumab and venetoclax after BTK inhibitors in CLL -
Trial result · Oct 15, 2026 · NCT03462719
Ibrutinib (BTK inhibitor) + venetoclax (BCL-2 inhibitor) improves long-term OS/PFS in 1L CLL, with more progression-free time without grade 3/4 AEs -
Trial result · Oct 15, 2026 · NCT03900598
Safimaltib (JNJ-67856633) MALT1 inhibitor posts 28.8% pooled ORR across heavily pretreated B-cell lymphomas and CLL, with frequent hyperbilirubinemia -
New trial · Oct 15, 2026 · NCT07516093
Phase 3 DAYBreak CLL-306 compares bexobrutideg BTK degradation with pirtobrutinib after covalent BTK inhibition -
New trial · Oct 15, 2026 · NCT07819214
Phase 2 epcoritamab CD3×CD20 consolidation seeks deeper remissions after at least 6 months of BTK inhibition in high-risk CLL